Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21(waf-1), and Ki-67 in multiple myeloma: Correlation with cyclin-D1 immunoreactivity

Modern Pathology

Volumn 11, Issue 7, 1998, Pages 642-647

  Lai, R ^a   Medeiros, L J ^a   Wilson, C S ^b   Sun, N C J ^c   Koo, C ^d   McCourty, A ^a   Brynes, Russell K ^a,e  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d KAISER FOUNDATION HOSPITAL   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cyclin D1; E2F 1; Immunohistochemistry; Ki 67; mdm 2; Multiple myeloma; p21(waf 1); p53

Indexed keywords

ARTICLE; CELL CYCLE; CORRELATION FUNCTION; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BONE MARROW CELLS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; ENZYME INHIBITORS; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031840937     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
2. Sellers WR, Kaelin WG. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997;15: 3301-12.
3. Nevins JR. A link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992;258:424-9.
4. Hunter T, Pines J. Cyclins and cancer. II. Cyclin D and cdk inhibitors come of age. Cell 1994;79:573-82.
5. Slansky JE, Farnham PJ. Introduction to the E2F family: protein structure and gene regulation. In: Farnham PJ, editor. Current topics in microbiology and immunology. Transcriptional control of cell growth: the E2F gene family. Vol. 208. Berlin: Springer-Verlag; 1996. p. 1-30.
6. Helin K, Harlow E. The retinoblastoma protein as a transcriptional repressor. Trends Cell Biol 1993;3:43-6.
7. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the pRb protein. Cell 1991;65:1053-61.
8. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. Waf1/Cip1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
9. Slansky JE, Li Y, Kaelin WG, Farnham PJ. A protein synthesis-dependent increase in E2F-1 mRNA correlates with growth regulation of the dihydrofolate reductase promotor. Mol Cell Biol 1993;13:1610-8.
10. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995;37: 691-4.
11. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993;13:301-6.
12. Hall M, Peter G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
13. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
14. Draetta GF. Mammalian G1 cyclins. Curr Opin Cell Biol 1994;6:842-6.
15. Vasef MA, Medeiros LJ, Yospur LS, Sun NCJ, McCourty A, Brynes RK. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol 1997;10:927-32.
16. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma: a retrospective and prospective study of 674 cases. Am J Clin Pathol 1987;87:342-55.
17. Helin K, Harlow E, Wu CL, Fattaey AR. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol 1993;13:6501-8.
18. Brynes R, McCourty A, Tamayo R, Jenkins K, Battifora H. Demonstration of cyclin D1 (bcl-1) in mantle cell lymphoma: enhanced staining using heat and ultrasound epitope retrieval. Appl Immunohistochem 1997;5:45-8.
19. Adams PD, Kaelin WG Jr. The cellular effects of E2F overexpression. In: Farnham PJ, editor. Current topics in microbiology and immunology. Transcriptional control of cell growth: the E2F gene family. Vol. 208. Berlin: Springer-Verlag; 1996. p. 79-93.
20. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
21. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancer. Science 1991;253:49-53.
22. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993;91:128-35.
23. Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, et al. p53 and N-ras oncogene mutations in multiple myeloma. Oncogene 1992;7:2539-43.
24. Hiyama H, lavarone A, LaBaer J, Reeves SA. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene 1997;14:2533-42.
25. waf1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 1997;90: 279-89.
26. Erber R, Klein W, Andl T, Enders C, Born AI, Conradt C, et al. Aberrant p21 (CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer 1997;74:383-9.
27. Polyak K, Waldman T, He T-C, Kinzler KW, Voglestein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996;10:1945-52.
28. Attadi LD, Lowe SW, Brugarolas J, Jacks Y. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 1996;15: 3693-701.
29. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
30. Boddy MN, Freemont PS, Borden KLB. The p53-associated protein mdm2 contains a newly characterized zinc-finger domain called the RING finger. Trends Biochem Sci 1994;19: 198-9.